Volatility is one of the things you’ll want to be prepared to address this season, depending on your nitrogen source. Nitrogen inhibitors, often referred to as stabilizers, are increasingly used by ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with ...

Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on the horizon ...

Patient- and physician-facing interventions together doubled the reductions in PPI use ...

BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell ...

Responses observed in patients with and without previous exposure to other KRAS G12C inhib ...

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...